Skip to main content
METabolic EXplorer logo

METabolic EXplorer — Investor Relations & Filings

Ticker · METEX ISIN · FR0004177046 LEI · 969500VI1GSBPGD9B460 PA Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2014-05-05 Annual Report
Country FR France
Listing PA METEX

About METabolic EXplorer

https://www.metabolic-explorer.com/

METabolic EXplorer (METEX) is an industrial biotechnology company specializing in the development and industrialization of fermentation bioprocesses. The company produces functional ingredients and chemical intermediates from renewable, non-food raw materials, offering sustainable alternatives to petrochemical processes. Its portfolio is centered on three main product families: 1,3-propanediol (PDO) for cosmetics, liquid polymers, and textiles; butyric acid (BA) for animal nutrition and the flavors and fragrances market; and amino acids for animal feed. The company operates through its subsidiaries, METEX NØØVISTA, which manages the PDO and BA production, and METEX NØØVISTAGO, which focuses on amino acids and ingredients for animal nutrition.

Recent filings

Filing Released Lang Actions
Rapport financier annuel 2013
Annual Report Classification · 100% confidence The document is titled 'RAPPORT FINANCIER ANNUEL 2013' (Annual Financial Report 2013) for the company Metabolic Explorer. It contains a comprehensive set of financial statements, management reports (Rapport de gestion), audit reports (Rapport des commissaires aux comptes), and consolidated accounts under IFRS for the fiscal year ending December 31, 2013. It is a full-length annual report, not an announcement or a summary, and thus fits the definition of a 10-K (Annual Report). FY 2013
2014-05-05 French
2013 : Une année faite de choix déterminants et des étapes en cours qui illustrent la stratégie d'industrialisation
Annual Report Classification · 95% confidence The document is a comprehensive annual review titled 'METabolic EXplorer en 2013', detailing the company's industrial and commercial activities, R&D milestones, financial strategy (Paceo), governance changes, and a section explicitly titled 'Résultats annuels 2013' (Annual Results 2013). It provides a detailed narrative of the fiscal year's performance and strategic outlook. While it contains financial highlights, it functions as the primary annual communication to shareholders regarding the company's yearly progress and results, fitting the definition of an Annual Report (10-K equivalent for this jurisdiction). FY 2013
2014-04-29 French
Industrialisation de la L-Méthionine, METabolic EXplorer et Roquette communiquent
Regulatory Filings Classification · 90% confidence The document is a press release dated April 4, 2014, announcing a change in the industrialization plan for the L-Methionine technology between METabolic EXplorer and Roquette. It details the termination of a previous contract and the establishment of a new agreement where METabolic EXplorer takes over the responsibility for industrialization and regulatory filings (like the expected FDA authorization). This is a strategic business update concerning partnerships and technology rights, not a standard periodic financial report (like 10-K or IR), a formal dividend announcement, or a management change announcement. It fits best under Capital/Financing Update (CAP) as it relates to the commercialization and structure of a major asset, or potentially Regulatory Filings (RNS) as a general corporate announcement. Given the focus on the termination of a development/industrialization contract and the transfer of commercialization rights, 'Capital/Financing Update (CAP)' is a strong candidate, although 'Regulatory Filings (RNS)' is often used for non-standard corporate actions. Since it is a specific announcement about a major business agreement and the future path of a key technology, and it is not a standard financial report, I will classify it as a general corporate announcement, which often falls under RNS if CAP is too focused on pure financing/fundraising. However, since it directly impacts the commercial strategy and future revenue stream, CAP is plausible. Let's re-evaluate against the definitions. It is not a standard ER, IR, 10-K, or DIV. It is a strategic business update. It is most similar to an announcement regarding a major business transaction or strategic shift. Given the options, and since it's a press release detailing a significant change in commercial strategy and asset ownership, it is best categorized as a general Regulatory Filing (RNS) or potentially a Capital Update (CAP) if the focus is seen as restructuring the commercialization capital. Since it is a press release announcing a change in agreements and strategy, RNS (Regulatory Filings - general regulatory announcements and fallback) is the safest classification for a non-standard strategic announcement that isn't explicitly covered elsewhere.
2014-04-04 French
METabolic EXplorer : Eligibilité au nouveau PEA-PME
Share Issue/Capital Change Classification · 99% confidence The document is a short press release dated April 3, 2014, announcing that METabolic EXplorer is eligible for the new PEA-PME (a French regulated investment scheme). It cites specific French decrees and financial criteria (employee count, revenue, balance sheet total). This type of announcement, which communicates a specific regulatory or financial status update outside of standard periodic reports (like 10-K or IR), fits best under the general 'Regulatory Filings' category (RNS) or potentially 'Capital/Financing Update' (CAP) due to the nature of the PEA-PME eligibility. Given that it is a specific, non-standard regulatory confirmation announcement, RNS is the most appropriate fallback, as it is not a standard earnings release (ER), dividend notice (DIV), or major shareholding change (MRQ). The document length is short (2981 chars), suggesting it is an announcement rather than a full report.
2014-04-03 French
Information relative au nombre total des droits de vote et d'actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 98% confidence The document title is "Déclaration du nombre total de Droits de Vote et d'Actions composant le capital social arrêté au 28/02/2014" (Declaration of the total number of Voting Rights and Shares comprising the share capital as of 02/28/2014). This explicitly details the total number of shares and voting rights, which aligns directly with the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it pertains to a specific, recurring statutory disclosure regarding voting power.
2014-03-21 French
Information relative au nombre total des droits de vote et d'actions composant le capital social
Major Shareholding Notification Classification · 99% confidence The document is very short (831 characters) and presents specific data points related to share capital ('Actions du capital'), theoretical voting rights ('Droits de vote théoriques'), and private voting rights ('Actions privées de droits de vote'). It cites Article 223-16 of the AMF general regulation, which typically relates to the disclosure of the total number of shares and voting rights. This structure strongly suggests a mandatory regulatory disclosure regarding the total number of shares and voting rights, often required monthly or quarterly. Since it is a specific, periodic disclosure of share/voting rights structure rather than a general announcement of a transaction (POS) or a change in major ownership (MRQ), and given the context of French regulatory filings (AMF), it most closely aligns with a specific regulatory disclosure. However, none of the provided codes perfectly match a 'Total Voting Rights Disclosure'. Given the options, it is a specific regulatory filing. It is not an AGM-R, 10-K, ER, or IR. It details the capital structure and voting rights, which is a specific regulatory disclosure. Since it is a direct disclosure of capital/voting rights structure, and not a general announcement of a report (RPA) or a general filing (RNS), and it doesn't fit DIRS, MRQ, or SHA precisely (which usually involve transactions or changes), the closest fit among the specific options related to capital structure disclosure is difficult. However, the content is a direct regulatory disclosure of the capital base and voting rights as of a specific date (31/01/2014). This type of disclosure is often mandated by stock exchange rules. Given the options, and recognizing it as a mandatory periodic disclosure of share structure, it is best categorized as a Regulatory Filing (RNS) if a more specific code like 'Total Voting Rights' is unavailable, or potentially related to Capital (CAP) or Share structure (SHA). Since it is a mandatory disclosure of the total number of shares and voting rights, which is a fundamental regulatory requirement, RNS (General Regulatory Filings) is the most appropriate fallback for this specific type of periodic disclosure not explicitly listed, although it is highly specific. If we must choose a specific code, it relates to the capital base, but it's not a financing event (CAP) or a share transaction (POS/SHA). I will classify it as RNS as a mandatory regulatory disclosure that doesn't fit the transactional or report announcement categories.
2014-02-27 French

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.